- Astatine is a radioactive chemical element
with the chemical symbol At and atomic number 85.
- It is highly radioactive and is only
available in tiny quantities. Its properties are inferred from its
position in the periodic table and by studying its chemistry in
extremely dilute solutions.
- It is the least chemically reactive of the
halogens and exhibits the most metallic properties of the halogen
group.
- It was made by bombarding bismuth-209 with
alpha particles in a cyclotron to produce, after emission of two
neutrons, astatine-211. The scientists found that the isotope they
created was radioactive, so they named the element using the Greek
‘astatos’ meaning unstable.
- It is now known that there are no stable
astatine isotopes – the longest lived isotope, astatine-210, has a
half-life of 8.3 hours.
- Three years later, astatine was found in
nature by Berta Karlik and Traude Bernert as an intermediate in
radioactive decay chains. Traces of the element appear naturally in
uranium and thorium minerals as a decay product. At any given time,
about 25 grams of naturally occurring astatine exists on our
planet.
- Astatine-211 is sometimes used as a
radioactive tracer and in cancer treatment.
Like iodine, it is known
to accumulate in the thyroid gland. Many chemical properties of astatine
have been determined using tracer studies on extremely dilute astatine
solutions.
Astatine has an electronegativity of 2.2 on the revised
Pauling scale. This is lower than that of iodine (2.66) and the same as
that of hydrogen. However, in hydrogen astatide (HAt) the negative
charge is predicted to be on the hydrogen atom, implying that this
compound should instead be referred to as astatine hydride
- The newly formed astatine-211 is important
in nuclear medicine. It can be used for targeted alpha particle
radiotherapy
|
General
- Atomic energy commission
radiochemistry of astatine
- General information
- pre-targeting of
Astatine-211 for therapy of metastatic prostate cancer
- Astatine-211 and Astatinated
radiopharmaceuticals
Technology
- Comparative Tissue
Distribution in Mice of the Emitter211Atand 13IIas Labels
of a
Monoclonal Antibody and F(ab')2 Fragment
- Biodistributions,
Myelosuppression and Toxicities in Mice Treated with an
Anti-CD45
Antibody Labeled with the α-Emitting Radionuclides
Bismuth-213 or Astatine-211
- Cytotoxicity of
particle-emitting astatine-211 Labeled
antibody in tumours
spheroids
- Online quantification of
211At at distillation
- Astatine standard redox
potentials and speciation in acidic medium
- Cellular Processing of
Astatinated EGF
After Binding to Cultured Carcinoma Cells
- Therapeutic efficacy of
astatine-211-labeled trastuzumab on radio resistant skov-3 tumors in
nude mice
- Tumor Induction with
Astatine-211 in Rats
Effect
- Astatine molecule stability
in vivo
- Radiobiological Effects of
Alpha-Particles from Astatine-211 From DNA Damage to Cell Death
- Radiolytic Effects on the
Chemical Behavior
of 211At
Uses
- Advances in the development
of Astatine
- Cytotoxicity of
oc-particle-emitting astatine-21 I Labeled
antibody in tumours
spheroids
- Effective cancer therapy
with the alpha-particle emitter astatine in a mouse model of genetically
modified sodium/iodide symporter-expressing tumors
- An update of the use of
boron cagemolecules in pendant groups for211At-labeling of
Biomolecular
|
Study
- Production of the alpha -
particle emitting radionuclide Astatine-211 at the Texas A&M
cyclotron institute
- Update on cyclotron
production studies of no-carrier-added
- Discovery of the astatine,
radon, francium, and radium isotopes
- Astatine molecule stability
in vivo
- About Astatine
- Comparative Cellular
Catabolism and Retention of Astatine
- Direct Procedure for
Astatination of Antibody Conjugate
Report
- Medical and health physics
quarterly report
- Astatine-211
radiochemistry
- Pre-targeting of
astatine-211 for therapy of metastatic prostate cancer
- Mass measurements of
astatine isotopes
- Chains, Energy and
Resources
Process
- Production and Assessment
of
211At for Targeted Alpha Therapy
- An all-solid state laser
system for the laser ion source RILIS and
in-source laser
spectroscopy of astatine
at ISOLDE/CERN
- Development of astatine ion
beams with RILIS
Patent
- Astatinated organic
compounds
- Process for isolation and
radiolabelling of pharmaceuticals with isotopes of astatine
- Hypervalent radioactive
astatine or iodine compounds and preparation methods thereof
Order the CD ROM Today |
|
Primary Information
Services
21 Murugappan St, SwamyNagar Ext2,
Ullagaram,
Chennai - 600091, India.
Phone: 91 44 22421080 mailto:informer@eth.netprimaryinfo@gmail.com
Mobile numbers:9940043898, 9444008898 Fax :
91 44 22423753 |